Teng Ai

Teng Ai is a Senior Scientist II at Arrowhead Pharmaceuticals, specializing in the development of novel therapies for muscular dystrophies, including ARO-DM1 for Myotonic Dystrophy Type 1 and ARO-DUX4 for Facioscapulohumeral muscular dystrophy, both in phase I clinical trials. Previously, Teng Ai served as a Senior Chemist at LKT Laboratories, Inc., focusing on new product development and synthetic route optimization. Academic experience includes a research associate position at the Center for Drug Design at the University of Minnesota, where Teng Ai designed and synthesized inhibitors and anti-HCV agents, as well as a postdoctoral role dedicated to novel hydroxamic acids. Earlier in the career, Teng Ai worked as a Research Chemist at Jiangsu Hansoh Pharmaceutical Co., Ltd., improving production processes for the anti-cancer drug Docetaxel. Teng Ai holds a Ph.D. in Organic Chemistry from Texas Tech University and a Master’s and Bachelor's degree in Chemistry from Nankai University.